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Introduction
Common variable immunodeficiency (CVID) is a hetero-
geneous group of primary immunodeficiency diseases char-
acterized by hypogammaglobulinemia and an increased 
susceptibility to recurrent infections, autoimmunity, and 
malignancy.1–6 Poor antibody responses to protein or 
polysaccharide antigens are a prominent finding in a par-
ticular group of patients.7–9 Several immunological mech-
anisms that affect B cells, T cells, and dendritic cells have 
been described in CVID,10–13 but the basic molecular 
defect that causes the disease is still unknown.14,15
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BACKGROUND/PURPOSE: Common variable immunodeficiency (CVID) is characterized by decreased 
serum levels of IgG and increased susceptibility to recurrent infections. The aim of this study was to evalu-
ate the IgG subclass levels of CVID patients.
METHODS: Twenty-four CVID patients who had been under regular intravenous immunoglobulin 
replacement therapy for 96.13 ± 54.83 months were enrolled in this study. Serum IgG and IgG subclass 
levels, and clinical outcomes for these patients were evaluated after this period of treatment.
RESULTS: Mean serum IgG levels were significantly increased from 272.91 ± 185.58 mg/dL at the time of 
diagnosis to 455.29 ± 200.23 mg/dL after treatment, while there was no significant difference in the serum 
levels of IgM and IgA. Decreased serum levels of IgG1 were detected in 75% of the patients studied. 
Decreased serum levels of IgG2, IgG3 and IgG4 were also detected in 6, 11, and 11 patients, respectively. 
All patients experienced recurrent infectious diseases either before, or after, diagnosis.
CONCLUSION: Although serum IgG levels in the patients significantly increased after regular intravenous 
immunoglobulin replacement therapy, serum IgM and IgA levels remained diminished over time. Further-
more, a number of cases had low levels of IgG subclasses, in spite of normal total IgG levels, which could 
explain why some patients had continued infections, even after immunoglobulin replacement therapy.
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Immunoglobulin replacement therapy is the treatment 
of choice for patients with hypogammaglobulinemia as 
it decreases the incidence and severity of infections, and 
improves the quality of life of these patients.16–23 However, 
in spite of regular immunoglobulin infusions, the serum 
IgG levels of some patients may not reach normal levels.
This study was performed to evaluate both serum IgG 
and IgG subclass levels in a group of CVID patients who 
were undergoing intravenous immunoglobulin (IVIG) re-
placement therapy for at least 2.5 years. Clinical outcomes 
were also evaluated.
Patients and Methods
Patients
This study was approved by the Ethical Committee of 
Tehran University of Medical Sciences. Written informed 
consent was obtained from all patients before sampling.
Twenty-four patients with CVID, who had been diag-
nosed and treated in the Division of Allergy and Clinical 
Immunology of Children’s Medical Center Hospital, were 
enrolled in this study. The diagnosis of CVID was based 
on standard criteria introduced by the European Society 
for Immunodeficiencies and the Pan-American Group 
for Immunodeficiency, and was also compatible with the 
new classification of primary immunodeficiency diseases 
introduced by the International Union of Immunological 
Societies.15,24 These include reductions in at least two of 
three serum immunoglobulin levels (IgG, IgM, IgA) by 
two standard deviations from the normal mean values for 
age, and genetic exclusion of other well-defined antibody 
deficiencies. In patients with low numbers of B cells, muta-
tion analysis of candidate genes for X-linked (BTK) and 
autosomal recessive (IGHM, CD79A, CD79B, IGLL1, BLNK) 
agammaglobulinemia was performed.25 The SH2D1A gene 
was analyzed in some susceptible male cases of X-linked 
lymphoproliferative syndrome. In some patients with 
normal or elevated serum IgM levels, the genes for CD40L, 
CD40, AID and UNG were sequenced due to suspicion of 
immunoglobulin class-switch-recombination deficiencies.6 
Patients under two years of age were excluded from this 
study because of a possible diagnosis of transient hypog-
ammaglobulinemia. All patients were under regular IVIG 
replacement therapy (300–600 mg/kg every 3–4 weeks) 
and followed-up for a period of at least 30 months.
Immunophenotyping
Immunophenotyping of fresh blood was performed by 
flow cytometry. The percentage of cells expressing CD 
markers was used as the unit of measurement. CD3+
T cells and CD19+ B cells were assessed. The percentages 
of CD3+CD4+ T cells and CD3+CD8+ T cells were also 
measured (Serotec, Oxford, United Kingdom).
Immunoglobulin assay
The first immunoglobulin assay was performed at the time 
of diagnosis. Subsequent assays were performed 3–4 weeks 
after IVIG replacement therapy, and just prior to the next 
scheduled immunoglobulin infusion. Serum immunoglob-
ulin levels (IgG, IgM, and IgA) and IgG subclasses (IgG1, 
IgG2, IgG3, and IgG4) were measured by nephelometry 
(The Binding Site, Birmingham, UK).
Period of disease
The course of disease was divided into pre- and post-
diagnosis, when IVIG replacement therapy was adminis-
tered to the patients. The time before diagnosis was the 
period between age of onset and age at diagnosis (diagnosis 
delay). The time after diagnosis was the period between age 
at diagnosis and the age at the time of the study (follow-up 
period). The number of infections, and hospital admis-
sions due to serious infections were calculated (per patient 
per year) and compared between the two periods. Recurrent 
infections were defined as more than three episodes of 
infection in the same organ.
Statistical analysis
Data analysis was performed using the SPSS version 
14.0 (SPSS Inc., Chicago, IL, USA). Data presented as 
the mean ± standard deviation and as median values 
(minimum–maximum). The χ2 test and Student’s t test 
were performed for some comparisons between the two 
periods. A p value of < 0.05 was considered significant.
Results
Patient characteristics
Twenty-four patients with CVID (17 male and 7 female) 
were investigated in this study. The median age at the time 
of diagnosis was 102.5 months (2–43 years), with a me-
dian diagnosis delay of 63.5 months (3–477 months). The 
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patients were followed-up for 96.13 ± 54.83 months (me-
dian, 78 months; range, 32–225 months), giving a total of 
2,307 patient-months (192.25 years). The mean age of 
patients at the time of the study was 19.49 ± 12.60 years 
(median, 16.17 years; range, 5–49 years).
Immunophenotyping
Lymphocyte subpopulation studies revealed that the num-
ber of CD3+ T cells was within the normal range accord-
ing to age (Figure 1). However, five patients had decreased 
percentages of CD19+ B cells (between 2% and 6%). 
A CD3+CD4+ T cells to CD3+CD8+ T cells of > 1 was 
found in 13 of the cases, while a reverse ratio was found in 
the remaining 11 cases (45.8%).
Serum immunoglobulin levels
The mean serum IgG concentration of the patients was 
272.91 ± 185.58 mg/dL at the time of diagnosis, while 
median serum IgM and IgA levels were 28.5 mg/dL 
(range, 0–140 mg/dL) and 5.5 mg/dL (range, 0–98 mg/dL), 
respectively.
Several immunoglobulin assays were performed after 
IVIG replacement therapy and the mean serum immu-
noglobulin levels calculated. Mean serum IgG was signi-
ficantly increased to 455.29 ± 200.23 mg/dL (p < 0.001), 
while there was no significant difference in IgM (p = 0.653) 
or IgA (p = 0.196) concentrations. The median serum IgM 
and IgA levels of the patients after IVIG replacement ther-
apy were 23.5 mg/dL (range, 0–150 mg/dL) and 5 mg/dL 
(range, 0–60 mg/dL), respectively (Figure 2).
IgG subclass levels
A cross-sectional evaluation of IgG and its subclasses 
in all cases revealed that half of the cases had a normal 
range of IgG concentration according to age. The mean 
serum IgG level was 613.25 ± 299.72 mg/dL, which was 
significantly higher than the level at the time of diagnosis 
(p < 0.0001). Although 11 patients had IgG serum levels 
of more than 600 mg/dL, decreased serum levels of IgG1 
were detected in 18 cases (75%), including five cases with 
a normal range of total IgG. Mean serum IgG1 levels 
were 348.46 ± 206.02 mg/dL. Decreased serum levels of 
IgG2 were found in six patients, while 11 patients had re-
duced serum levels of IgG3 for their age. Decreased serum 
levels of IgG4 were also found in 11 cases (Table 1). The 
mean serum IgG2, IgG3, and IgG4 levels were 215.51 ± 
104.63 mg/dL, 37.79 ± 31.59 mg/dL, and 1.11 ± 0.71 mg/dL, 
respectively.
Clinical outcome
Infection was the most common clinical manifestation, 
either before diagnosis, or after IVIG replacement therapy. 
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Figure 1. Absolute number of B and T cell subpopulation in 
patients.
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Figure 2. Box plot figure of serum immunoglobulin levels at the 
time of diagnosis and 3–4 weeks after the intravenous immu-
noglobin replacement therapy. IVIG = intravenous immunoglobin 
replacement therapy.
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Table 1. Serum IgG subclass levels of common variable immunodeficiency patients (n = 24)
Patient no. Sex Age (yr) IgG (mg/dL) IgG1 (mg/dL) IgG2 (mg/dL) IgG3 (mg/dL) IgG4 (mg/dL)
  1 M 47 639.10 243.80a 352.10 27.55a 1.09
  2 F 16 837.00 365.50a 407.80 57.83 1.58
  3 F 7 836.20 315.60a 366.50 19.80 1.03
  4 M 49 1,099.00 693.30 222.70 1.12a 1.59
  5 M 9 1,376.00 956.50 227.10 103.90 1.73
  6 M 49 426.70a 206.90a 73.36a 26.17a 0.70a
  7 M 14 434.50a 177.10a 77.94a 22.62a 3.11
  8 M 17 990.80 685.30 197.80 87.07 0.61a
  9 M 20 354.40a 217.70a 83.06a 30.19 1.58
 10 M 26 433.40a 218.00a 230.70 17.66a 0.43a
 11 F 31 352.10a 266.80a 108.30a 24.11a 0.53a
 12 F 18 536.30a 234.40a 303.10 35.95 0.41a
 13 M 9 578.80a 320.90a 233.60 14.85a 2.19
 14 M 16 560.70a 315.80a 243.90 18.33a 0.97a
 15 M 9 456.80a 211.50a 141.80 77.62 1.21
 16 F 18 760.90 383.40a 276.90 24.07a 1.12a
 17 M 21 130.00a 150.00a 95.00a 0.00a 0.00a
 18 M 5 392.00 209.70a 156.00 11.78 0.53a
 19 M 16 22.20a 16.40a 11.57a 0.00a 0.00a
 20 M 10 747.10 418.00 325.10 13.11 1.51
 21 F 12 692.30 438.60 284.50 64.37 1.10
 22 F 22 545.90a 339.60a 249.90 94.72 1.05
 23 M 12 837.40 576.60 307.60 51.28 0.88a
 24 M 16 678.30 401.60a 196.00 82.77 1.81
aDecreased serum levels according to age.
The most commonly encountered infections were pneu-
monia (21 patients), diarrhea (21 patients), sinusitis (19 
patients), and otitis media (16 patients). Other, less fre-
quent, infections were conjunctivitis (8 patients), cuta-
neous infections (8 patients), and five patients each with 
superficial abscesses, mucocutaneous candidiasis, and 
septic arthritis. Bronchiectasis was documented in seven 
patients. While recurrent infections were significantly de-
creased in comparison with the period before diagnosis 
after IVIG replacement therapy, the number of patients 
who had upper respiratory tract infections did not signifi-
cantly differ between the two time periods (Table 2). The 
incidence of hospital admission due to severe infection 
significantly reduced from 1.21/patient/year pre-diagnosis, 
to 0.125/patient/year during IVIG replacement therapy 
(p = 0.008).
Discussion
CVID is a heterogeneous group of disorder with different 
immunological phenotypes.1–3,26,27 Recurrent infectious 
complications before diagnosis are the most common man-
ifestations, and some patients continue to experience such 
infections after treatment. In this survey, we studied both 
the serum IgG and IgG subclass levels in CVID patients 
undergoing regular IVIG replacement therapy for more 
than 30 months.
Hypogammaglobulinemia is the main feature of CVID. 
Thus immunoglobulin replacement therapy, either intra-
venous or subcutaneous, is recommended as the approved 
treatment in this group of patients.6 As shown in this 
study, such treatment decreases the rate of recurrent and 
severe infections and consequent hospitalization.16–23 
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Although immunoglobulin replacement therapy has 
changed the spectrum of diseases, several medical compli-
cations are still observed in these patients. In this study, 
while recurrent infections were significantly decreased after 
IVIG replacement therapy, there was no significant differ-
ence in the number of patients who had upper respiratory 
tract infections between the two time periods. Pneumonia 
was the most common manifestation, followed by diar-
rhea, sinusitis, and otitis media. Although CVID patients 
are susceptible to recurrent infections at different sites, it 
seems that the respiratory and gastrointestinal systems 
are more involved.1,2,28
Twenty one out of 24 CVID patients had recurrent 
pneumonia, and one third of these cases developed bron-
chiectasis. Although the rate of pneumonia decreased 
significantly after IVIG replacement therapy, respiratory 
infections should be considered as a common medical 
problem in CVID patients, and failure to provide adequate 
im munoglobulin replacement therapy could lead to early 
bronchiectasis.
In this study, the patients only rarely experienced re-
current upper respiratory tract infections after IVIG ther-
apy, while there was no significant difference in number 
of patients who had a single episode of either otitis media 
or sinusitis between the two periods. It seems that upper 
respiratory tract infections continue to be important 
problems in hypogammaglobulinemic patients, even after 
treatment with immunoglobulin substitution. It has been 
shown that such treatment cannot eradicate such infec-
tions after late diagnosis, possibly due to structural 
damage in the mucociliary system.29,30
Nearly all the CVID patients in this study had de-
creased serum immunoglobulin levels before treatment. 
Although serum IgG levels in these patients significantly 
increased after regular IVIG replacement therapy, the lev-
els of IgM and IgA were stable over time. However, it seems 
that some patients do not reach normal levels, and have 
a deficit of IgG and/or IgG subclasses. A number of cases 
had decreased IgG subclass levels, in spite of normal total 
IgG levels, which shows the importance of IgG monitor-
ing after IVIG administration. Such deficiencies in immu-
noglobulin levels could explain why a number of patients 
continue to have infections, even after immunoglobulin 
replacement therapy.
It is important to consider CVID in any patient, even 
pediatric cases, with a history of recurrent infections. As-
sessment of the immune system, including measurement 
of serum immunoglobulin levels, IgG subclass levels, anti-
body responses to polysaccharide antigens, and lymphocyte 
subset enumeration should be performed for such pa-
tients. The serum immunoglobulin levels of the patients 
should also be checked regularly; this helps physicians to 
manage these patients.
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Table 2. Comparison of respiratory and gastrointestinal infections in common variable immunodeficiency patients before and 
after diagnosis
Infections Before diagnosis After diagnosis p
Otitis media 14 (58.3) 9 (37.50) 0.240
Recurrent otitis mediaa 11 (45.8) 1 (4.17) 0.002
Sinusitis 17 (70.8) 11 (45.80) 0.140
Recurrent sinusitisa 6 (25.0) 1 (4.17) 0.048
Pneumonia 21 (87.5) 6 (25.00) < 0.001
Recurrent pneumoniaa 10 (41.7) 1 (4.17) 0.006
Diarrhea 20 (83.3) 7 (29.20) 0.004
Recurrent diarrheaa 12 (50.0) 1 (4.17) 0.001
aMore than three episodes of infection.
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